Bristol Myers Squibb Company $BMY Stake Trimmed by SteelPeak Wealth LLC

SteelPeak Wealth LLC lowered its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 89.9% in the third quarter, HoldingsChannel.com reports. The firm owned 4,841 shares of the biopharmaceutical company’s stock after selling 43,310 shares during the quarter. SteelPeak Wealth LLC’s holdings in Bristol Myers Squibb were worth $302,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Davis Asset Management L.P. bought a new position in shares of Bristol Myers Squibb during the second quarter worth approximately $27,000. Addison Advisors LLC bought a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $32,000. Groupe la Francaise boosted its stake in shares of Bristol Myers Squibb by 562.9% in the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 501 shares during the period. Arlington Trust Co LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $35,000. Finally, Kilter Group LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $35,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $61.76 on Wednesday. The company has a market cap of $126.15 billion, a price-to-earnings ratio of 9.04, a PEG ratio of 0.29 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The firm has a 50 day simple moving average of $63.39 and a 200 day simple moving average of $60.28. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.77 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Wall Street Analyst Weigh In

A number of research firms have commented on BMY. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Leerink Partners lowered Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $73.00 to $59.00 in a report on Monday, October 5th. Roth Capital started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating and a $75.00 target price on the stock. Finally, Daiwa Securities Group raised their price target on Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $64.88.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: RBC expects Bristol Myers Squibb to exceed third-quarter revenue estimates, reinforcing optimism ahead of the company’s earnings report. RBC expects a third-quarter revenue beat for Bristol Myers Squibb stock
• Positive Sentiment: Bristol Myers Squibb is scheduled to present new oncology data at ESMO 2026, including results for pumitamig, izalontamab brengitecan (iza-bren), and the Opdivo-Yervoy combination. Positive data could support the company’s pipeline and long-term growth outlook. Bristol Myers Squibb Heads To ESMO 2026 With New Oncology Data
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, substantial free-cash-flow generation, and dividend yield of approximately 4.3%. Goldman Sachs also upgraded the stock, adding to bullish sentiment. Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Bristol Myers Squibb Upgraded at The Goldman Sachs Group
• Neutral Sentiment: Investor attention across the pharmaceutical sector is elevated ahead of cancer-drug presentations, with Moderna also attracting buying interest. That broader oncology focus may be helping sentiment toward BMY, although the Moderna catalyst is not directly related to Bristol Myers Squibb. Moderna Jumps While Melanoma Vaccine Data Looms
• Negative Sentiment: The company still faces the challenge of replacing revenue from aging blockbuster medicines. Upcoming ESMO results could either validate its pipeline strategy or increase concerns about future growth. Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.